Rein Therapeutics
RNTX
23 hedge funds and large institutions have $11M invested in Rein Therapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
238% more capital invested
Capital invested by funds: $3.24M → $11M (+$7.71M)
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
15% more funds holding
Funds holding: 20 → 23 (+3)
12.78% more ownership
Funds ownership: 21.75% → 34.53% (+13%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.22M |
| 2 |
SM
Senvest Management
New York
|
+$1.11M |
| 3 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$246K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$172K |
| 5 |
Renaissance Technologies
New York
|
+$81.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$9.82K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$986 |
| 3 |
BlackRock
New York
|
-$576 |
RNTX Hedge Fund Activity: Q1 2024 in Review
23 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Rein Therapeutics (RNTX) for Q1 2024, worth a combined $11M — up 238% from $3.24M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new RNTX positions and 1 closed out — a net gain of 3 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $1.22M. The largest seller was UBS Group, cutting an estimated $9.82K.
- 23 institutional investors held Rein Therapeutics (RNTX) as of Q1 2024, up from 20 in Q4 2023.
- Funds reported $11M of Rein Therapeutics stock for Q1 2024, up 238% quarter-over-quarter.
- 4 funds opened new Rein Therapeutics positions in Q1 2024 and 1 closed out, a net change of +3 holders.
- The largest Rein Therapeutics buyer in Q1 2024 was Nantahala Capital Management, an estimated $1.22M added.
- The largest Rein Therapeutics seller in Q1 2024 was UBS Group, an estimated $9.82K sold.
Based on aggregated 13F filings for Q1 2024.